PRESSEFACH
WEITERE ADHOC-MELDUNGEN
Weng Fine Art beschließt Veräußerung von 50.000 eigenen Aktien
Veröffentlichung einer Kapitalmarktinformation
Alternative Gegenleistung zum freiwilligen Erwerbsangebot für Biofrontera-Aktien
Korrektur zur Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vertriebspartnerschaft mit SoftwareCentral
Ferax Capital AG veröffentlicht Halbjahreszahlen 2018
SHF Communication Technologies AG hebt Umsatz- und Ergebnisprognose für das Geschäftsjahr 2018 an
 
MELDUNG VOM 04.12.2017 07:30
Meldung drucken Artikel weiterleiten
pta20171204005
Business news for the stock market
Pressefach Pressefach

Medigene AG: Medigene announces participation at upcoming investor and scientific conferences

Planegg (pta005/04.12.2017/07:30) - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at four upcoming investor and scientific conferences:

American Society of Hematology (ASH) Annual Meeting
Date: 9 - 12 December 2017
Location: Atlanta, USA

Guggenheim's 5th Annual Boston Healthcare Conference
Date: 13 December 2017
Location: Boston, USA

JP Morgan Healthcare Conference
Trout Access
Date: 8 - 11 January 2018
Location: San Francisco, USA

ODDO BHF Forum 2018
Date: 11 - 12 January 2018
Location: Lyon, France

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(Ende)

Aussender: Medigene AG
Lochhamer Straße 11
82152 Planegg
Deutschland
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 33 3301
E-Mail:
Website: www.medigene.de
ISIN(s): DE000A1X3W00 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Medigene AG
AKTUELLE BUSINESS NEWS
20.07.2018 17:30
Filterhersteller Dexwet drängt an die NASDAQ
Dexwet International AG
20.07.2018 13:47
Deutsche Start-ups verzichten auf Geld vom Staat
pressetext.redaktion
20.07.2018 10:00
D.A.S.: Zehntes Mal in Folge mit A-Rating
D.A.S. Rechtsschutz AG
20.07.2018 06:10
"Atmosphärische Führung" steigert Produktivität
pressetext.redaktion
19.07.2018 11:30
Griechenlands Privatwirtschaft hat kaum Potenzial
pressetext.redaktion
Weitere News anzeigen